Virtual Library

Start Your Search

Pedro Rocha

Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      81P - Higher PD-L1 expression correlates with lymphocyte infiltration in early non-small cell lung cancer (ID 396)

      12:30 - 13:00  |  Presenting Author(s): Pedro Rocha

      • Abstract
      • Slides


      Patients with advanced NSCLC (Non-small cell lung cancer) benefit from ICIs (immune checkpoint inhibitors) as part of their treatment strategy. This benefit might also be observed in earlier stages. The aim of our work was to characterize the immune contexture of early NSCLC and assess the impact on outcome of immune biomarkers.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      Formalin-fixed paraffin embedded (FFPE) 1 mm cores from patients that underwent curative surgical treatment between 2006 and 2018 at Hospital del Mar (Barcelona, Spain), and did not received neoadjuvant therapy were included in a tissue microarray. PD-L1 expression as well as CD3, CD4, CD8, CD80 and CD103 were evaluated by immunohistochemistry. We report the percentage of positive cells for each marker from all nucleated cells. We evaluated the association between clinicopathological and molecular characteristics and immune biomarkers (Mann-Whitney, Kruskal-Wallis and Spearman correlation) and their impact on survival outcomes (Cox regression).

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      Samples from 195 patients were included (Adenocarcinomas N = 130, Squamous cell carcinoma N = 61, Other histology N = 4). In our cohort, 74.9% of the cases were males, predominantly smokers (87.2%). Tumor size was less or equal than 40mm in 72.3% of the cases. Stage I, II, III and IV tumors represent 44.6%, 25.1% and 26.7% of all cases included in our study, respectively. PD-L1 expression was <1%, 1 - <50% and ³50%, in 46.7%, 29.2% and 24.1% of the cases respectively. PD-L1 expression was positively correlated with higher percentage of CD4 (rho=0.195), CD8 (rho=0.3272), CD80 (rho=0.2152) and CD103 (rho=0.4237) (all p-values<0.05). CD103 expression was positively correlated with CD80 expression (rho=0.514; p < 0.001). A higher percentage of lymphocytes measured by CD3 expression in tumor tissue was correlated with better overall survival (p = 0.045; HR = 0.98 (0.96-0.99)) when adjusted by TNM 8thedition stage and adjuvant chemotherapy. No correlations with clinicopathological features were observed.

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      Immune biomarker expression is highly heterogeneous in early NSCLC. Lymphocyte infiltration is associated with higher PD-L1 expression. Evaluation of immune biomarkers might better inform the choice of adjuvant treatment for NSCLC patients.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      The authors.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      All authors have declared no conflicts of interest.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.